What Has Driven the Growth of the Brain Tumor Drugs Market in Recent Years?
The brain tumor drugs market has seen considerable growth due to a variety of factors.
• Over past years, the brain tumor drugs market has seen significant expansion. The projections indicate that it will increase from $3.81 billion in 2024 to around $4.09 billion in 2025, with a compound annual growth rate (CAGR) of approximately 7.2%.
Factors contributing to this growth during the historical period include a rising prevalence of neurological disorders, hikes in healthcare spending, more approvals for oncology (cancer) drugs, an upsurge in pharmaceutical R&D expenditure, and advancements in cancer drug development.
What Is the Forecasted Market Size and Growth Rate for The Brain Tumor Drugs Market?
The brain tumor drugs market is expected to maintain its strong growth trajectory in upcoming years.
• In the upcoming years, it is anticipated that the brain tumor drugs market will experience a robust growth, reaching $5.27 billion by 2029 with a compound annual growth rate (CAGR) of 6.6%.
The acceleration during the forecast period can be ascribed to factors such as a surge in cancer incidence, increased spending in healthcare, a rise in aging population, a strong lineup of drug products, and revised FDA regulations promoting biologics drug development. Key trends to watch during the forecast period encompass efforts to invest in a mix of drugs for treating brain tumors, the adaptation of phase zero clinical trials for enhanced effectiveness, leveraging technology for better drug delivery systems, emphasis on expanding cell and gene therapy, and executing strategic mergers and acquisitions.
Which Drivers Are Accelerating Growth In The Brain Tumor Drugs Market?
The escalating occurrence of Neurological Disorders globally is the key driver for the expansion of the Brain Tumor drugs market. The prevalence of these disorders is growing due to factors such as increased life expectancy, amplified exposure to infections, and passive lifestyles. To illustrate, the National Brain Tumor Society reports an alarming 700,000 individuals in the United States living with a primary brain tumor, with an estimated 86,000 more expected to receive a diagnosis. This upward surge in neurological disorders, inclusive of brain tumors, is fueling the demand for drugs used for their treatment, thereby driving the growth of the brain tumor drugs market.
What Are The Main Segments Of The Global Brain Tumor Drugs Market?
The brain tumor drugs market covered in this report is segmented –
1) By Drugs: Temozolomide, Bevacizumab, Other Drugs
2) By End User: Hospital Pharmacies, Retail Pharmacies Or Drug Stores, Other End-Users
Subsegments:
1) By Temozolomide: Oral Formulation, Injectable Formulation
2) By Bevacizumab: Monoclonal Antibody Therapy, Combination Therapy With Chemotherapy
3) By Other Drugs: Carmustine, Lomustine, Etoposide, Irinotecan, Novantrone (Mitoxantrone)
Pre-Book The Brain Tumor Drugs Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Influencing The Growth Of The Brain Tumor Drugs Market?
In the brain tumor drugs market, companies are shifting their attention to the implementation of nanotechnology for therapy. The utilization of nanoparticles to convey medication in combination directly to the cancerous cells or the tumor has been employed. This approach has not only decreased the drug dosage but also enhanced its longevity and reduced harmful effects. Some nano drugs have been successful in overcoming the blood-brain barrier, a significant hurdle in treating brain tumors. Case in point, Liposomes nanoparticles can deliver drugs to the cancerous cells easily, and if coated with transferrin, they can even cross the blood-brain barrier. Corporations such as GE Healthcare, Sigma-Tau Pharmaceuticals Inc., Johnson & Johnson, Merck & Company Inc., Pfizer, Inc., and Celgene Corporation are incorporating this technology to enhance the existing medication and treatment methods.
Who Are the Key Players in the Brain Tumor Drugs Market?
Major companies operating in the brain tumor drugs market include:
• F. Hoffmann-La Roche Ltd
• Novartis AG
• Amgen Inc.
• Pfizer Inc.
• Merck & Co. Inc.
• CordenPharma
• Eisai Co. Ltd.
• Emcure Pharmaceuticals Limited
• Y-mAbs Therapeutics
• Roche India
• Novartis Oncology
• Arlak Biotech
• Healthkind Labs Pvt. Ltd.
• SwisscheM Healthcare Pvt.Ltd
• Apikos Pharma
• Kolaz Biotech
• CStone Pharma
• CARsgen Therapeutics
• JW Therapeutics
• BeiGene
• Astellas Pharma Inc
• Otsuka Pharmaceutical Co. Ltd
• Daiichi Pharmaceutical and Sankyo
• AQVIDA GmbH
• Baxter International Inc. (UK)
• AstraZeneca plc
• GlaxoSmithKline plc
• Veropharm
• Biocad
• Bristol-Myers Squibb
• Celon Pharma
• Celgene Corporation
• Johnson & Johnson
• Eli Lilly and Company
• Sandoz AG
• Eurofarma Laboratórios S.A.
• TUTEUR Argentina
• The Takeda Pharmaceutical Company Limited
• Pierre Fabre Group
• Celnova Pharma
• Pfizer S.R.L.
• Teva Pharmaceutical Industries Ltd.
• BIOPHARMA-MEA
• NeoTX
• AID Genomics Limited
• Julphar
• Sanofi
• Novo Nordisk A/S
• Bayer
• Kitov Pharma Limited
• CureTech Ltd.
• Neopharma
• Eurolab
• Aspen
• Adcock Ingram.
What Is The Most Dominant Region In The Brain Tumor Drugs Market?
North America was the largest region in the brain tumor drugs market in 2024. Middle East is expected to be the fastest-growing region in the global brain tumor drugs market share during the forecast period. The regions covered in the brain tumor drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
